Trial Profile
A controlled, randomized, assessor blinded, open-label study to investigate whether initiation of everolimus will reduce the incidence of developing a new Squamous Cell Carcinoma (SCC) and other malignancies in Renal Transplanted Recipients with at least one SCC during the last 2 years
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin
- Indications Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SESAM
- 04 Oct 2016 New trial record